Page last updated: 2024-11-07

4-guanidinobenzoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-guanidinobenzoate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-guanidinobenzoic acid : Benzoic acid substituted at the para position by a guanidino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID159772
CHEMBL ID20767
CHEBI ID125204
SCHEMBL ID211005
MeSH IDM0081557

Synonyms (33)

Synonym
p-guanidinobenzoic acid
4-guanidinobenzoic acid
4-carbamimidamidobenzoic acid
4-guanidino-benzoic acid
DB02459
1jz ,
4-guanidinobenzoate
CHEBI:125204 ,
16060-65-4
CHEMBL20767
4-amino(immino)methylaminobenzoate
bdbm50014341
4-(diaminomethylideneamino)benzoic acid
A810154
AKOS006228263
4-((aminoiminomethyl)amino)benzoic acid
para-guanidinobenzoate
FT-0686410
SCHEMBL211005
SXTSBZBQQRIYCU-UHFFFAOYSA-N
4-guanidino benzoic acid
STL426033
BBL034734
mfcd00152515
bdbm237208
DTXSID90936349
Q27093453
benzoic acid, 4-[(aminoiminomethyl)amino]-
D85799
WS-02983
CS-0185073
EN300-107692
PD007991

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally."( Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
Babu, YS; Bantia, S; Chand, P; Chu, N; Cole, LB; Kotian, PL; Laver, WG; Montgomery, JA; Pathak, VP; Petty, SL; Shrout, DP; Walsh, DA; Walsh, GM, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Ki0.48000.00021.10439.9000AID725593
Prothrombin Bos taurus (cattle)IC50 (µMol)342.50000.00890.88576.0000AID1803131
PlasminogenHomo sapiens (human)Ki10,000.00000.01701.15604.4000AID157989
Urokinase-type plasminogen activatorHomo sapiens (human)IC50 (µMol)342.50000.03703.385910.0000AID1803131
Urokinase-type plasminogen activatorHomo sapiens (human)Ki744.86600.01702.62687.0000AID215841; AID215976
Cationic trypsinBos taurus (cattle)IC50 (µMol)342.50000.00003.479210.0000AID1803131
Cationic trypsinBos taurus (cattle)Ki10,000.00000.00001.07539.0000AID215213; AID215237
Chymotrypsin-like elastase family member 1Sus scrofa (pig)IC50 (µMol)342.50002.18525.171310.0000AID1803131
Carbonic anhydrase 1Homo sapiens (human)Ki0.63000.00001.372610.0000AID725595
Carbonic anhydrase 2Homo sapiens (human)Ki1.15000.00000.72369.9200AID725594
Carbonic anhydrase 9Homo sapiens (human)Ki2.56000.00010.78749.9000AID725592
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
proteolysisProthrombin Bos taurus (cattle)
acute-phase responseProthrombin Bos taurus (cattle)
positive regulation of blood coagulationProthrombin Bos taurus (cattle)
protein polymerizationProthrombin Bos taurus (cattle)
proteolysisPlasminogenHomo sapiens (human)
blood coagulationPlasminogenHomo sapiens (human)
negative regulation of cell population proliferationPlasminogenHomo sapiens (human)
negative regulation of cell-substrate adhesionPlasminogenHomo sapiens (human)
extracellular matrix disassemblyPlasminogenHomo sapiens (human)
tissue regenerationPlasminogenHomo sapiens (human)
fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationPlasminogenHomo sapiens (human)
myoblast differentiationPlasminogenHomo sapiens (human)
muscle cell cellular homeostasisPlasminogenHomo sapiens (human)
tissue remodelingPlasminogenHomo sapiens (human)
biological process involved in interaction with symbiontPlasminogenHomo sapiens (human)
negative regulation of fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of fibrinolysisPlasminogenHomo sapiens (human)
trophoblast giant cell differentiationPlasminogenHomo sapiens (human)
labyrinthine layer blood vessel developmentPlasminogenHomo sapiens (human)
mononuclear cell migrationPlasminogenHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionPlasminogenHomo sapiens (human)
negative regulation of cell-cell adhesion mediated by cadherinPlasminogenHomo sapiens (human)
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisCationic trypsinBos taurus (cattle)
digestionCationic trypsinBos taurus (cattle)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
serine-type endopeptidase activityProthrombin Bos taurus (cattle)
calcium ion bindingProthrombin Bos taurus (cattle)
protein bindingProthrombin Bos taurus (cattle)
fibrinogen bindingProthrombin Bos taurus (cattle)
protease bindingPlasminogenHomo sapiens (human)
endopeptidase activityPlasminogenHomo sapiens (human)
serine-type endopeptidase activityPlasminogenHomo sapiens (human)
signaling receptor bindingPlasminogenHomo sapiens (human)
protein bindingPlasminogenHomo sapiens (human)
serine-type peptidase activityPlasminogenHomo sapiens (human)
enzyme bindingPlasminogenHomo sapiens (human)
kinase bindingPlasminogenHomo sapiens (human)
protein domain specific bindingPlasminogenHomo sapiens (human)
apolipoprotein bindingPlasminogenHomo sapiens (human)
protein-folding chaperone bindingPlasminogenHomo sapiens (human)
protein antigen bindingPlasminogenHomo sapiens (human)
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
endopeptidase activityCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCationic trypsinBos taurus (cattle)
protein bindingCationic trypsinBos taurus (cattle)
metal ion bindingCationic trypsinBos taurus (cattle)
serpin family protein bindingCationic trypsinBos taurus (cattle)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
extracellular regionPlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
plasma membranePlasminogenHomo sapiens (human)
external side of plasma membranePlasminogenHomo sapiens (human)
cell surfacePlasminogenHomo sapiens (human)
platelet alpha granule lumenPlasminogenHomo sapiens (human)
collagen-containing extracellular matrixPlasminogenHomo sapiens (human)
extracellular exosomePlasminogenHomo sapiens (human)
blood microparticlePlasminogenHomo sapiens (human)
Schaffer collateral - CA1 synapsePlasminogenHomo sapiens (human)
glutamatergic synapsePlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexCationic trypsinBos taurus (cattle)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID725592Inhibition of human CA9 by stopped-flow assay2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors.
AID215213Inhibition against Trypsin1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses.
AID243684Percentage inhibition against tryptase at 10 uM2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
Combinatorial approaches towards the discovery of new tryptase inhibitors.
AID94678In vivo blood glucose was determined in obese, hyperglycemic, hyperinsulinemic, insulin-resistant KKAy mice after a dose of 500 mg/kg for 4 days2001Journal of medicinal chemistry, Apr-12, Volume: 44, Issue:8
Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent.
AID210841Inhibition against human plasma thrombin at 1.0 mM1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses.
AID215976log1/Ki value was calculated against Urokinase-type plasminogen activator1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses.
AID95039Inhibition against human plasma Kallikrein at 2 mM1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses.
AID215841Inhibition against Urokinase-type plasminogen activator1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses.
AID725595Inhibition of human CA1 by stopped-flow assay2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors.
AID725596inhibition of human PAD4 preincubated at 10 uM for 15 mins before substrate addition measured after 20 mins by spectrophotometry2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors.
AID147482In vitro inhibitory activity against H1N9 strain of Influenza neuraminidase (membrane) at 7 mM concentration1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
AID725594Inhibition of human CA2 by stopped-flow assay2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors.
AID157989Inhibition against human plasmin was determined at 0.5 mM1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses.
AID210572Inhibition against Tissue plasminogen activator at 1 mM1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses.
AID725597inhibition of human PAD4 preincubated at 1 uM for 15 mins before substrate addition measured after 20 mins by spectrophotometry2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors.
AID725593Inhibition of human CA12 by stopped-flow assay2013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors.
AID215237log1/Ki value was calculated against Trypsin1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses.
AID1803131Enzyme Assay from Article 10.3109/14756366.2010.616860: \\Polyphenol fatty acid esters as serine protease inhibitors: a quantum-chemical QSAR analysis.\\2012Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 27, Issue:6
Polyphenol fatty acid esters as serine protease inhibitors: a quantum-chemical QSAR analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (20.00)18.7374
1990's5 (33.33)18.2507
2000's4 (26.67)29.6817
2010's2 (13.33)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.83 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]